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High Frequency of BRAFV600E Mutation in Acquired
Nevi and Small Congenital Nevi, but Low Frequency
of Mutation in Medium-Sized Congenital Nevi
Nami Ichii-Nakato1, Minoru Takata1, Shuko Takayanagi1, Shiho Takashima1, Jingrong Lin1, Hiroshi Murata1,
Akihide Fujimoto2, Naohito Hatta3 and Toshiaki Saida1
To investigate whether the frequency of the BRAFV600E (V-raf murine sarcoma virus oncogene homolog B1)
mutation in melanocytic nevi is associated with sun exposure patterns, we examined 120 acquired melanocytic
nevi excised from various anatomic sites, including glabrous skin, as well as 62 congenital nevi. We used a new
mutation detection system based on the shifted termination assay, called Mutector, which was able to detect
only 5% of heterozygous mutant cells within the samples. We detected the mutation in 105/120 (87.5%) acquired
nevi and 43/62 (69.4%) congenital nevi. Notably, we found the mutation in 35/43 (81.4%) acquired nevi excised
from glabrous skin and genitalia. These results strongly suggest that UV light is not necessarily required for the
acquisition of the BRAFV600E mutation, and suggest that non-mutagenic effects of UV light to melanocytes may
be more important in the nevogenesis. Additionally, we showed heterogeneous distribution of BRAF-mutated
cells within the lesions of small congenital nevi by a combination of laser microdissection and direct
sequencing. Finally, we found low frequency of BRAFV600E mutation (6/20, 30.0%) in medium-sized congenital
nevi. Most of these nevi with wild-type BRAF had neroblastoma ras viral oncogene homolog mutations (9/14,
64.3%), suggesting different pathogenesis of medium-sized congenital nevi from acquired nevi and small
congenital nevi.
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INTRODUCTION
Melanocytic nevus and cutaneous malignant melanoma are
both melanocytic neoplasia, which have common genetic
and environmental risk factors. Individuals with fair skin, with
a tendency to sunburn, and those who do not tan are at an
increased risk for cutaneous melanoma (Bataille, 2003), and
so are those with an increased number of melanocytic nevi
(Bauer and Garbe, 2003). Numerous epidemiological studies
have suggested that the number of melanocytic nevi is the
major risk marker for the development of cutaneous
melanoma (Bauer and Garbe, 2003). Sun exposure, particu-
larly before the age of 20, has been suggested to play a role in
melanoma development (Elwood and Jopson, 1997), and also
has a major role in the genesis of acquired melanocytic nevi
(Gallagher and McLean, 1995). The relationship between
sunlight exposure and the development of these melanocytic
neoplasms, however, is complex, and cannot be fully
explained simply on the basis of lifetime sun exposure. For
example, melanomas frequently occur on skin covered by
clothing (Gallagher and McLean, 1995; Elwood and Jopson,
1997), and indoor workers often suffer higher rates of
melanoma than outdoor workers (Elwood and Jopson,
1997). Although the nevus density is higher on continuously
versus intermittently exposed body sites, it peaks at earlier
ages, around 9–14 (Gallagher and McLean, 1995). These
apparent paradoxes might be explained by understanding the
molecular genetic events that translate the effect of solar
exposure into the development of melanomas and nevi.
Recently, a high frequency of oncogenic BRAF (V-raf
murine sarcoma virus oncogene homolog B1) mutations at a
single site in the kinase domain of the exon 15 has been
reported in melanomas and melanocytic nevi, suggesting that
the mutational activation of the RAS/RAF/MEK/ERK pathway
is a critical step in the development of these melanocytic
tumors (Davies et al., 2002; Pollock et al., 2003). This T to A
transversion at codon 600 of the BRAF gene, resulting in a
V600E amino-acid missense mutation, would be useful to
investigate the etiological relevance of UV light to the genesis
of melanocytic neoplasia. However, the relationship between
the BRAFV600E mutation and sun exposure is not clear either,
because the mutations do not have the standard UVB
signatures, such as those in the p53 gene frequently found
in non-melanoma skin cancers (Sarasin, 1999). Furthermore,
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a recent investigation examining the distribution of BRAF
mutations across different melanoma types showed that BRAF
mutations were most commonly found in melanomas on skin
subject to intermittent sun exposure than elsewhere, and that
mutation frequencies were low in anatomic areas that receive
the lowest (mucosa and glabrous skin) and the highest sun
exposure (face) (Maldonado et al., 2003). These findings raise
the interesting possibility that there may exist several distinct
genetic pathways leading to melanoma in relation to sun
exposure (Rivers, 2004). However, whether the same pattern
of the uneven distribution of BRAF mutations depending on
sun exposure exists in melanocytic nevi is not known.
To further understand the relationship between BRAF
mutations, sun exposure, and the development of melano-
cytic neoplasia, we have examined BRAF mutations in 120
acquired nevi excised from various anatomic sites with
different levels of sun exposure. We have also examined 62
congenital nevi that must have developed independently of
UV light. Although several previous studies have reported
BRAF mutations in different types of melanocytic nevi
(Pollock et al., 2003; Uribe et al., 2003; Yazdi et al., 2003;
Loewe et al., 2004; Saldanha et al., 2004; Turner et al.,
2005), the present investigation is the first comprehensive
mutation analysis examining a large number of cases
including both acquired and congenital nevi.
RESULTS
Comparison of sensitivity for detecting the BRAFV600E mutation
between direct sequencing and the Mutector assay
To ascertain the sensitivity of direct sequencing and the
Mutector assay to detect the BRAFV600E mutation, we
performed titration assays (Figure 1). Genomic DNA of
MM-AN, a melanoma cell line containing heterozygous
BRAFV600E mutation, was admixed with blood DNA obtained
from a normal individual. Serially diluted DNA samples
containing 100–0.01% of the cell line DNA were subjected to
direct sequencing and the Mutector assay. Direct sequencing
required more than 20% cell line DNA within a given DNA
sample to detect the mutation. In other samples, containing
less than 20% of cell line DNA, the presence of a mutant
peak was not reliably discernable from background spikes.
By contrast, the Mutector assay gave positive results when the
mutant cell line DNA comprised 5% or more of the mixture.
The results confirmed the high sensitivity of the Mutector
assay in detecting the BRAF mutation from contaminated
samples (Shackelford et al., 2004).
High frequency of BRAFV600E mutation in acquired nevi,
including those from glabrous skin and genitalia
To examine whether the BRAFV600E mutation rates were
different according to the anatomical localization, we first
analyzed a total of 120 acquired nevi excised from various
body sites. Direct sequencing revealed the BRAFV600E
mutation in 47 (39.2%) of 120 acquired nevi (Table 1 and
Table S2). Although another type of mutation at codon 600
(GTG to GAT) was reported in a melanoma cell line (Davies
et al., 2002), we did not find such mutation. At variance with
direct sequencing, the mutation was detected in 105 (87.5%)
samples by the Mutector assay (Table 1 and Table S2). With
the sensitive Mutector assay, we found mutations in most of
the samples irrespective of anatomical localizations. All 30
nevi excised from intermittently sun-exposed sites contained
BRAF-mutated cells. Notably, 81.4% of acquired nevi
excised from non-exposed body sites (i.e., glabrous skin
and genitalia) also showed mutation.
We also tested whether other variables, such as patient’s
age, histological type, and size of nevi, affect the BRAF
mutation frequency. The BRAF mutation was detected in
86% (61/71) of patients under the mean age of 37 years old
and in 90% (44/49) of patients over 37 years old,
respectively. By subgrouping lesions according to size, 85%
(55/65) of nevi larger than 6.5 mm and 91% (50/55) of nevi
smaller than 6.5 mm, respectively, showed the BRAF muta-
tion. By subgrouping lesions according to histopathological
types, we found the BRAF mutation in 89% (17/19) of
junctional nevi, in 87% (39/45) of compound nevi, and in
88% (49/56) of dermal nevi. None of these differences were
statistically significant.
High frequency of BRAFV600E mutation in small congenital nevi,
but low frequency of mutation in medium-sized congenital nevi
In congenital melanocytic nevi, the BRAFV600E mutation
frequency differed markedly between small (o1.5 cm) and
medium-sized (X1.5 cm) nevi (Table 2). Small congenital
nevi showed the mutation as frequently as did acquired nevi,
the mutation being detected in 61.9% of samples according
to the direct sequencing and 88.1% by the Mutector assay,
respectively. By contrast, the mutation rate was much lower
in medium-sized congenital nevi. Even with the Mutector
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Figure 1. Sensitivity of the BRAFV600E mutation detection by direct
sequencing and the Mutector assay. Titration assay was performed using
genomic DNA samples of a melanoma cell line, MM-AN, which had a
heterozygous BRAFV600E mutation, serially diluted with normal blood DNA.
Direct sequencing detected the heterozygous T to A mutation (arrow) in
samples containing more than 20% of cell line DNA. Mutector was positive
by both visual judgment and the OD ratio (greater than 2.0) in samples
containing more than 5% of cell line DNA.
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assay, the mutation was detected in only six (30%) of 20
samples. The difference of the mutation rate detected by the
Mutector assay between small- and medium-sized congenital
nevi was statistically significant (Po0.0001 by the w2 test).
Different from acquired nevi and small congenital nevi, the
mutation rates detected by direct sequencing and the
Mutactor assay were almost identical in medium-sized
congenital nevi. Only one junctional medium-sized con-
genital nevus on the back of an 11-year-old girl showed
discrepant results (Table 3).
To look for the mutations other than BRAFV600E in
medium-sized congenital nevi, we examined mutations of
the codon 61 of the NRAS (neroblastoma ras viral oncogene
homolog) gene. We found nine mutations at codon 61 (eight
Q61 K mutations and one Q61R mutation) (Table 3). All of
the cases with NRAS mutations were wild-type for BRAF.
Heterogeneous distribution of BRAF-mutated nevus cells within
a lesion
Unexpectedly, we found marked difference in the BRAF
mutation frequency between direct sequencing and the
Mutector assay in acquired nevi and small congenital nevi
(Tables 1 and 2). In a total of 154 samples of acquired nevi
and small congenital nevi, 60 samples were found to be
Table 1. BRAFV600E mutations are frequent in acquired nevi regardless of the anatomic sites
Direct sequencing Mutector1
Wild Mutation % Wild Mutation %
Category Number Age (mean) Sex Site Histology (V600E) (95% CI) (V600E) (95% CI)
Chronically exposed sites 47 9–82 (42) M (11) Face (42) Compound (9) 25 22 46.8 7 38 84.4
F (36) Neck (4) Dermal (38) (32.5–61.1) (73.9–95.0)
Back of hand (1)
Intermittently exposed sites 30 9–53 (31) M (7) Back (12) Compound (13) 13 17 56.7 0 28 100
F (23) Abdomen (7) Dermal (16) (38.9–74.4) (100–100)
Chest (5) Junctional (1)
Leg/arm (6)
Non-exposed sites 43 7–83 (35) M (13) Sole (36) Compound (23) 35 8 18.6 8 35 81.4
F (30) Palm (4) Dermal (2) (7.0–30.2) (69.8–93.0)
Genitalia (3) Junctional (18)
Total 120 7–83 (37) M (31) Compound (45) 73 47 39.2 15 101 87.1
F (89) Dermal (56) (30.4–47.9) (81.0–93.2)
Junctional (19)
1Mutector assay was not performed for four nevi that showed mutation by direct sequencing.
Table 2. Lower frequency of the BRAFV600E mutation in medium-sized congenital nevi than in small congenital nevi
Direct sequencing Mutector1
Wild Mutation % Wild Mutation %
Category Number Age (mean) Sex Site Histology (V600E) (95% CI) (V600E) (95% CI)
Small (o15 mm) 42 0–56(26) M (13) Face (18) Back (14) Compound (16) 16 26 61.9 5 33 86.8
**
F (29) Chest (1) Sole (6) Dermal (24) (47.2–76.6) (76.1–97.6)
Palm (1) Junctional (2)
Leg/arm (2)
Medium (X15 mm) 20 1–51(19) M (4) Back (6) Neck (2) Compound (12) 15 5 25 14 6 30
F (16) Sole (2) Face (1) Dermal (6) (6.0–44.0) (9.9–50.1)
Leg/Arm (9) Junctional (2)
Total 62 0–56(24) M (17) Compound (28) 31 31 50 19 39 67.2
F (45) Dermal (30) (37.6–62.4) (55.2–79.3)
Junctional (4)
1Mutector assay was not performed for four small congenital nevi that showed mutation by direct sequencing.
**Po 0.0001 by w2-test.
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BRAF mutation positive by both methods. For all 20 samples
found to be BRAF mutation negative by the Mutector assay,
direct DNA sequencing showed wild-type BRAF. In the
remaining 74 samples (48.1%), however, while direct
sequencing showed wild type, the Mutector assay was
positive. The difference of the results was most prominent
in acquired nevi excised from non-exposed sites, in which
direct sequencing revealed the mutation in only eight
(18.6%) samples (Tables 1, 2 and Tables S2, S3). This is not
surprising, because 42% of nevi from non-exposed sites were
small junctional nevi, from which we were not able to dissect
pure nevus cell populations. It appears that the sensitive
Mutector assay picked up a small proportion of BRAF-
mutated nevus cells within the samples admixed with normal
keratinocytes, as well as dermal stromal cells. Surprisingly,
however, a substantial number of acquired nevi from
chronically and intermittently sun-exposed sites as well as
small congenital nevi, which showed wild-type BRAF by
direct sequencing, were positive for the Mutector assay.
These nevi were either compound or dermal nevi, from
which relatively pure nevus cell populations were obtained
by dissection. Given that the sensitivity of mutation detection
by direct sequencing was more than 20% of cells with the
heterozygous mutation within the sample, contamination of
non-nevus cells was unlikely to account for the discrepant
results. To rule out the possibility of technical artifacts, such
as PCR contaminations in the Mutector assay, we repeated
the assay from the original DNA (not from purified PCR
products prepared for direct sequencing) in 14 randomly
selected samples (six positive, eight negative), and obtained
results completely identical to the original assay. We also
tested the 11 DNA samples from normal skin (six of them
were from the head and neck) with the Mutector assay, but all
of them gave negative results. Thus, the most likely
explanation for the discrepant results in these larger nevi is
that minor populations of nevus cells with BRAF mutation are
present in these lesions, which were detected only with the
sensitive Mutector assay.
To prove directly this thought, we performed laser
microdissection followed by direct sequence in three cases
of small congenital nevi. In the initial analyses of DNA
samples obtained by macrodissection, all of these three nevi
had shown wild-type BRAF by direct sequencing, whereas
the Mutactor assay had been positive. We microdissected
clusters of nevus cells from 6–12 different areas within the
lesions. An example of microdissection and sequence
analysis is shown in Figure 2. Direct sequencing identified
BRAF mutation in 2/12 (case 15), 3/6 (case 17), and 4/6 (case
39) microdissected samples, respectively, whereas all the
other samples showed wild-type sequence. As shown in
Table 3. NRAS codon 61 mutations are common in medium-sized congenital nevi
BRAF codon 600
Case Age Sex Site Size (cm) Histology Direct sequencing Mutector1 NRAS codon 61
1 18 F Lower leg 10.0 6.0 Compound GTG-GAG 12.2 Wild type
2 11 F Upper leg 4.0 1.7 Compound GTG-GAG 9 Wild type
3 26 F Lower leg 4.5 2.8 Junctional GTG-GAG 12.1 Wild type
4 16 F Neck 2.0 2.0 Dermal GTG-GAG 15 Wild type
5 25 M Back 1.6 1.4 Compound Wild type 1.15 Wild type
6 12 F Upper leg 2.6 1.2 Compound Wild type 1.36 CAA-AAA
7 16 F Upper leg 3.5 2.5 Compound Wild type 0.24 CAA-AAA
8 1 F Back 13.0 7.0 Dermal Wild type 0.11 Wild type
9 11 F Back 7.0 3.0 Junctional Wild type 3.55 Wild type
10 15 M Neck 1.8 1.5 Compound Wild type 0.94 CAA-CGA
11 51 F Sole 2.5 1.7 Compound Wild type 1.65 Wild type
12 33 F Sole 1.7 9.0 Dermal Wild type 1.73 Wild type
13 23 M Back 6.4 3.0 Compound Wild type 0.02 Wild type
14 48 F Back 1.5 1.0 Compound Wild type 0.05 CAA-AAA
15 19 M Face 2.3 1.8 Dermal Wild type 0.83 CAA-AAA
16 6 F Lower leg 3.0 1.5 Compound Wild type 0.72 CAA-AAA
17 9 F Upper arm 4.3 2.7 Compound Wild type 0.65 CAA-AAA
18 20 F Back 5.0 2.2 Dermal Wild type 0.62 CAA-AAA
19 5 F Upper leg 4.0 3.0 Dermal GTG-GAG 2.17 Wild type
20 5 F Upper leg 8.0 3.0 Compound Wild type 0.66 CAA-AAA
1OD ratio, a ratio greater than 2 (bold letters) indicates mutation.
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Figure 2, the distribution of areas that showed BRAF mutation
was random, and was not related to the localization (i.e.,
upper dermis or lower dermis) or morphological types (i.e.,
types A–C) of nevus cells. The result provides direct evidence
of clonal heterogeneity of nevus cells within a single lesion in
terms of BRAF mutation status, and is very likely to explain
the discrepant results between direct sequencing and the
Mutector assay in the initial macrodissected samples.
DISCUSSION
It is believed that both melanoma and nevi are caused, at
least in part, by excessive exposure to UV irradiation
(Jhappan et al., 2003). Because UV light is a well-known
mutagen, it is assumed that the BRAFV600E mutations
frequently detected in both melanoma and nevi may be
caused directly by UV irradiation. However, the T to A
transversion at codon 600, which accounts for more than
90% of mutations of the BRAF gene (Davies et al., 2002), is
not the standard mutation signature of either UVB (Brash
et al., 1991) or UVA (Drobetsky et al., 1995). The BRAFV600E
mutations are common in the cells of papillary thyroid
carcinoma (Xing, 2005), a cancer obviously not related to UV
exposure. This study also showed a high frequency of the
BRAFV600E mutation in congenital nevi and acquired nevi
from non-exposed skin, such as soles of the foot and
genitalia, both of which must have developed independently
of UV light. However, the results should be interpreted with
caution, because there is uncertainty about whether all
congenital nevi, which were defined by patient’s or parent’s
testimony, were really present at birth, and because there is a
chance of UV exposure even on soles of the foot and
genitalia. Nevertheless, the high frequency of BRAFV600E
mutations in these nevi strongly suggests that UV exposure is
not necessarily required for generating BRAFV600E mutations.
UV light induces several carcinogenic effects to melanocytes
other than direct mutagenesis (Jhappan et al., 2003). It has
been suggested that UV light acts as an independent
melanocyte mitogen, directly activating cell surface growth
factor receptors by oxidative stress-mediated protein tyrosine
phosphatase inhibition (Gross et al., 1999). UV light also
activates melanocortin 1 receptor, which could potentially
induce melanocyte growth (Abdel-Malek et al., 1999).
Finally, and perhaps most importantly, UV light mediates
the upregulation of critical melanocyte growth factors, such
as endothelin-1 and basic fibroblast growth factor, originating
from adjacent keratinocytes and fibroblasts (Archambault
et al., 1995; Tada et al., 1998). These non-mutagenic effects
of UV light to melanocytes may be more important in the
development of melanocytic nevi, and are likely to explain
the epidemiological link between UV light exposure and the
number of melanocytic nevi, although the possibility still
remains that the direct mutagenesis of UV light may be
responsible for the genesis of acquired nevi on sun-exposed
body sites.
Recently, Loewe et al. (2004) retrospectively selected 49
melanocytic lesions, which did not meet the criteria of
melanoma at initial presentation. These lesions showed either
an increase in size or structural changes after a 12-month
follow-up by the use of dermoscopy. Histopathologically, 24
of these lesions were melanoma, whereas the remaining 25
were melanocytic nevi. Samples from these lesions and from
35 randomly selected additional lesions with no change
during follow-up were sequenced for their BRAF mutation
status. The authors detected BRAF mutations in five of 25 nevi
with growth and/or structural change, whereas mutations
were found only in two of 35 nevi without morphological
changes. Based on this finding, that rapidly growing nevi are
more likely to have the BRAF mutation but dormant nevi do
not, the authors suggested that BRAF mutation contributes to
enhanced nevus growth, and that BRAF mutation may
determine lesions at risk of developing into melanoma.
However, we found BRAF mutations in the majority of a large
series of acquired nevi. The majority of nevi examined in this
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Figure 2. Heterogenous distribution of the BRAFV600E mutation within a
lesion of a small congenital nevus. (a) Histopathology of a small congenital
nevus from the face of a 48-year-old woman (case 39 in Table S3) before
microdissection. Bar¼ 100mm. Insets show epithelioid nevus cells with
melanin pigment in the papillary dermis (left) and smaller nevus cells with
scant cytoplasm in the lower dermis (right). Bar¼ 10mm. (b) The same section
after laser-capture microdissection. Six different areas were dissected.
Samples from areas 2, 3, 4, and 5 showed mutation, whereas those from 1 and
6 were wild-type. The distribution of mutation was not related to the
localization or morphological types of nevus cells. Bar¼ 100mm. (c)
Sequencing traces of DNA extracted from six microdissected areas. Although
the initial direct sequencing analysis using macrodissected DNA did not
detect mutation, mutant peaks of (A) are apparent in lanes 2, 3, 4, and 5
(arrows), confirming the presence of nevus cells harboring BRAFV600E
mutation within this lesion. In contrast, samples dissected from areas 1 and 6
showed wild-type BRAF. Small peaks of (A) are also seen in these two lanes,
but they are indistinguishable from noise peaks.
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study were raised nevi, which were unlikely to have shown
morphological changes, as well as to develop into melano-
mas. Thus, our results dispute the view by Loewe et al. (2004)
that there may be some link between BRAF mutation and
malignancy. Loewe et al. (2004) analyzed mutation by
mutation allele-specific PCR and direct sequencing in
macrodissected tissues. The difference from the present study
in the methods of mutation screening may explain the low
mutation frequency in the non-growing nevi reported by
Loewe et al. (2004).
Although previous studies by Pollock et al. (2003) and
Yazdi et al. (2003), respectively, found BRAF mutations in 6/7
(86%) and 6/13 (46%) of congenital nevi, the size of nevi
analyzed were not described. Papp et al. (1999, 2005)
analyzed NRAS and BRAF gene mutations in 18 congenital
nevi with known clinical details. These included 15 medium-
sized nevi exceeding 1.5 cm in diameter, and found BRAF
mutations in six (40%) nevi. We also identified the BRAFV600E
mutation in only 6/20 (30%) nevi exceeding 1.5 cm in
diameter. The BRAF mutation frequency was significantly
lower than that in small congenital nevi (37/42, 88.1%) and
acquired nevi (105/120, 87.5%). Interestingly, both studies
found a high frequency of NRAS codon 61 mutations in
medium-sized congenital nevi, which possessed wild-type
BRAF (Papp et al., 1999), and we, respectively, detected
NRAS mutations at codon 61 in 8/9 (88.9%) and 9/14
(64.3%) medium-sized congenital nevi, which were wild-
type for BRAF. Most of the NRAS mutations found in both
studies were CAA (Glu) to AAA (Lys) mutations (Papp et al.,
1999). These results indicate that mutations of NRAS, rather
than BRAF, are common in medium-sized congenital nevi.
This difference in the oncogene mutation profiles between
small- and medium-sized congenital nevi is interesting, and
may have clinical relevance. Generally, a nevus larger than
1.5 cm is very likely a congenital nevus, and, in a lesion of
this size, a corroborative parental history that the lesion was
present at birth is quite probable. However, small (o1.5 cm)
congenital nevi have many overlaps in clinical and histo-
pathological characteristics with acquired nevi, and the
evidence, that small nevi represent as congenital were indeed
present at birth, is less than compelling (Elder, 1985). Our
data show, also from molecular genetic aspects, that small
(o1.5 cm) congenital nevi are similar to acquired nevi, and
that medium-sized (X1.5 cm) congenital nevi are distinct
from them. NRAS activates both the phosphatidylinositol-30
kinase pathway and the mitogen-activated protein kinase
pathway, whereas BRAF activates only the latter, suggesting
that the NRAS mutations may exert stronger growth signals
resulting in the formation of larger nevi. However, there was
no difference in the actual size of the congenital nevi
between those with BRAF mutations and those with NRAS
mutations (Table 3). It is also of great interest whether this
genetic difference between small- and medium-sized con-
genital nevi may affect their malignant potential. However,
currently there is no evidence that the risk of developing
melanoma is different between small- and medium-sized
congenital nevi (Zaal et al., 2004). Very recently, Raeve et al.
(2006) detected no BRAF mutations in 26 giant congenital
nevi, which are definitely associated with increased risk of
developing melanoma (Zaal et al., 2004). It would be very
interesting to examine NRAS mutations in giant congenital
nevi.
An unexpected finding from the present study is a marked
difference in mutation detection between direct sequencing
and the Mutector assay in acquired nevi and small congenital
nevi. A substantial number of nevi examined in our study
showed wild-type BRAF by direct sequencing, whereas the
more sensitive Mutector assay were positive. A previous
study examining clinical samples from thyroid carcinomas
showed 100% concordances of BRAFV600E mutation detec-
tion by direct sequencing with the Mutector assay (Xing et al.,
2004). It is unlikely that PCR artifacts such as contaminations
may account for the positive Mutector reaction. The most
likely explanation for the discrepant results between the two
methods is that nevus cells are polyclonal in terms of BRAF
mutation status within the lesions of these cases, and that
only the sensitive Mutector assay could detect minor
populations of cells harboring BRAF mutation. With a
combination of laser-capture microdissection and direct
sequencing, we convincingly showed that BRAF mutation-
positive and -negative nevus cell populations were admixed
within the lesions of three small congenital nevi. It is believed
that nevi are benign tumors of cutaneous melanocytes
(Magana-Garcia and Ackerman, 1990). Several clonality
analyses using PCR-based X-chromosome inactivation assays
showed the clonal nature of melanocytic nevi (Robinson
et al., 1998; Hui et al., 2001; Indsto et al., 2001), whereas
one study found polyclonal X–chromosome inactivation
patterns (Harada et al., 1997). Furthermore, it was recently
suggested that nevi are senescent clones of melanocytes,
which temporarily underwent proliferation by concogenic
BRAF signaling (Michaloglou et al., 2005). Most of these
previous investigations suggest that nevi are clonal neo-
plasms. However, our results challenge this notion, and
warrant further investigations.
MATERIALS AND METHODS
Tissue samples
Paraffin-embedded tissue blocks of 62 congenital nevi and 120
acquired melanocytic nevi were retrieved from the archives of the
Department of Dermatology, Shinshu University Hospital (Matsu-
moto, Japan) and of the Department of Dermatology, Kanazawa
University Hospital (Kanazawa, Japan). All the patients were
Japanese. The detailed clinical data of the cases are shown in
Tables 1–3 and Tables S2–S3. We determined the definition of the
degree of sun exposure according to the paper by Green (1992).
Hairy scalp and back of the neck of a female were included in the
intermittent exposed site. Most of the acquired nevi on chronically or
intermittently sun-exposed sites were raised nevi, and excised on
request of the patient, mainly for cosmetic reasons. On the other
hand, most of the nevi on the palms and soles were flat nevi, and
excised for histopathological diagnosis because nearly half of the
cutaneous melanoma in the Japanese population arise from glabrous
skin (Ishihara et al., 2001). All the congenital nevi were present at
birth according to the medical records at the time of excision. For
patients under the age of 18, the presence of the nevus at birth was
2116 Journal of Investigative Dermatology (2006), Volume 126
N Ichii-Nakato et al.
BRAF Mutations in Melanocytic Nevi
mostly confirmed by an accompanying parent. According to the
classification by Kopf et al. (1979), 42 of them were small congenital
nevi less than 1.5 cm in diameter, whereas the remaining 20 were
medium-sized congenital nevi between 1.5 and 19.9 cm in diameter.
This retrospective study was approved by the medical ethical
committee of the Shinshu University School of Medicine, and
conducted according to the Declaration of Helsinki Principles. For
excisions, patients gave written informed consent.
Tissue dissection and DNA preparation
We macrodissected nevus cells from 10-mm paraffin-embedded
tissue sections using a no. 15 surgical blade, referring to the
corresponding hematoxylin- and eosin-stained pathology slides. For
dermal nevi and compound nevi with predominant dermal
components, the dissection was easy, and the contamination of
keratinocytes and stromal cells was estimated to be less than 25%. In
contrast, for junctional nevi and small compound nevi, a dissection
of relatively pure nevus cell populations was impossible, and whole
the epidermis and the papillary dermis, which contained nevus cell
nests, were removed for DNA preparation. We extracted DNA using
a MagneSil Genomic Fixed Tissue System (Promega, Madison, WI),
according to the protocol of the manufacturer.
Laser microdissection
Using a PALM-MB microdissection system (PALM Microlaser
Technologies, Bernried, Germany), we obtained a total of 24
samples from three small congenital nevi (cases 15, 17, and 39 in
Table S3). All of them were dermal nevi. With the initial analyses of
DNA samples obtained by macrodissection, these three nevi had
shown wild-type BRAF by direct sequencing, whereas the Mutactor
assay had been positive. Before microdissection, sections were
deparaffinized in xylene, rehydrated in ethanol, and stained with 1%
methylene blue. We microdissected several clusters of nevus cells
from different parts and different depths of the dermis (Figure 2). The
captured cells were transferred to 10 ml of digestion buffer containing
proteinase K and incubated at 501C for 16 hours. Before PCR,
proteinase K was inactivated at 901C for 10 minutes.
Mutation analyses for the BRAF gene
To detect the BRAF mutations, we amplified exon 15 of the BRAF
gene by PCR. PCR primers are described previously (Davies et al.,
2002). The primer sequences and PCR cycling conditions were given
in Table S1. PCR products were purified with QIAquick (Qiagen,
Valencia, CA), and directly sequenced using Big Dye Terminator
sequencing chemistry (Applied Biosystems, Foster City, CA) and the
sense primer. Sequencing reactions were analyzed on an ABI
automated sequencer (Applied Biosystems, Foster City, CA).
Because the use of direct sequencing as the sole method of
mutation analysis may miss some mutations in samples with non-
nevus cell contamination (Miller et al., 2004), we also performed a
novel and sensitive shifted termination assay, which detects the T to
A missense mutation at codon 600 of the BRAF gene, using the
Mutector complete kit (TrimGen Co., Sparks, MD) (Shackelford
et al., 2004). In brief, 1 ml of purified PCR products used for direct
sequence was re-amplified using a primer pair (Cohen et al., 2004)
(Table S1), which yielded a 102-bp fragment of exon 15. The
amplification was verified with 2% agarose gel electrophoresis. Ten
microliters each of the PCR products was subjected to the
hybridization with detection primer, primer extension reaction,
and colorimetric detection following the manufacturer’s protocol.
The colorimetric signal was measured with a 405-nm absorbance
filter on a microplate reader (Bio-Rad Laboratories, Hercules, CA). A
positive result is indicated when the ratio of the optical density of the
specimen minus the blank to the optical density of the wild-type
control sample minus the blank was greater than two. The results
were always concordant with the visual examinations of color
development.
Mutation analyses for the NRAS gene
For medium-sized congenital nevi, we also analyzed the mutations
at codon 61 of the NRAS gene. PCR primers and amplification
protocols for exon 3 (formally designated as exons 2) of the NRAS
gene were those described earlier (Davies et al., 2002). We carried
out sequencing in the reverse direction. The mutations at codon 61
were verified by a different nested-PCR method, as described earlier
(Houben et al., 2004) (Table S1).
Statistical analysis
We used the w2 test and the Fisher’s exact test to examine the
difference of the BRAFV600E mutation frequency. A P-value of lower
than 0.05 was considered significant.
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